Welcome to Transmolecular.com
TransMolecular, Inc. is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies for glioma, metastatic brain tumors, and aggressive cancers with limited treatment options.
Our experienced team is dedicated to expediting the research and approval processes necessary to bring promising new treatment options – as well as renewed hope – to millions of patients who need them.
In the pages of this website, you will find information about:
| • | High-grade glioma and other cancers that are the focus of our current research |
| • | Our management and clinical research teams |
| • | TransMolecular, Inc.’s proprietary products and technology |
| • | Progress-to-date on our glioma clinical trial program and other clinical trial programs |
| • | Our plans for future development |
TransMolecular Presents Imaging and Pharmacokinetic Analysis of 131Iodine-TM601 at Society for Nuclear Medicine Meeting
read
more 
TransMolecular Reports Positive Results from Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma
read
more
TransMolecular Initiates Phase 1 Clinical Trial for Unlabeled TM601 in
Recurrent Malignant Glioma
read
more
TransMolecular Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at AACR Annual Meeting
read
more
